LKFT Lakefront Biotherapeutics NV IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1421876 · Reporting currency EUR
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY303.5%
TTM net income YoY333.1%
TTM EPS YoY334.8%
Revenue 3-yr CAGR66.4%
Net income 3-yr CAGR—
Margins
Gross margin97.3%
Operating margin26.5%
Net margin28.9%
FCF margin-24.4%
EBITDA margin—
Returns
ROE10.5%
ROA8.5%
ROIC (approx.)9.9%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets5.0%
Debt / equity0.00x
Current ratio20.15x
Interest coverage285.34x
Cash quality & payout
Operating cash flow / net income-0.80x
Accruals ratio15.3%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 1.11B | 275.65M | 239.72M | 241.25M | 234.38M |
| Cost of revenue | 29.74M | 34.86M | — | 12.08M | 1.63M |
| Gross profit | 1.08B | 240.79M | — | 229.17M | 232.75M |
| R&D expense | 459.42M | 335.46M | 241.29M | 269.80M | 320.50M |
| SG&A expense | 147.33M | 117.25M | 128.29M | 135.16M | 127.74M |
| Operating income | 295.04M | -188.34M | -88.26M | -131.06M | -171.57M |
| Interest expense | 1.03M | 911,000 | 1.77M | 6.88M | 11.59M |
| Pretax income | 300.87M | -3.08M | 5.62M | -70.85M | -119.40M |
| Income tax | -18.62M | -1.80M | 9.61M | 572,000 | 1.39M |
| Net income | 320.88M | 74.08M | 211.70M | -217.99M | -103.23M |
| EPS (basic) | 4.87 | 1.12 | 3.21 | -3.32 | -1.58 |
| EPS (diluted) | 4.87 | 1.12 | 3.21 | -3.32 | -1.58 |
| Weighted avg. shares (diluted) | 65.90M | 65.90M | 65.88M | 65.70M | — |
| Balance sheet | |||||
| Cash & equivalents | 87.87M | 64.24M | 166.80M | 508.12M | 2.23B |
| Short-term investments | 2.91B | 3.05B | 3.52B | 3.59B | 2.47B |
| Receivables | 20.71M | 47.48M | 28.45M | 40.43M | 111.34M |
| Inventory | 22.49M | 51.19M | 73.98M | 52.92M | 20.57M |
| Current assets | 3.08B | 3.34B | 3.86B | 4.24B | 4.86B |
| PP&E, netmay include right-of-use assets (IFRS) | 71.95M | 105.40M | 111.22M | 126.73M | 105.72M |
| Goodwill | — | 70.01M | 69.56M | 69.81M | — |
| Intangibles | 848,000 | 164.86M | 127.91M | 146.35M | 60.10M |
| Total assets | 3.41B | 4.14B | 4.36B | 4.73B | 5.19B |
| Current liabilities | 152.86M | 335.08M | 428.22M | 522.54M | 566.47M |
| Total liabilities | 170.65M | 1.24B | 1.56B | 2.21B | 2.55B |
| Shareholders' equity | 3.24B | 2.90B | 2.80B | 2.53B | 2.64B |
| Cash flow statement | |||||
| Operating cash flow | -257.46M | -320.03M | -405.97M | -500.54M | -503.83M |
| Capital expenditure | 13.70M | 16.72M | 18.71M | 27.39M | 54.20M |
| Free cash flow | -271.16M | -336.75M | -424.68M | -527.93M | -558.03M |
| Investing cash flow | 288.81M | 220.60M | 71.19M | -1.25B | 541.24M |
| Financing cash flow | -3.27M | -4.92M | -5.00M | -1.49M | -3.88M |
| Stock-based compensation | 24.00M | 19.89M | 56.72M | 88.51M | 70.73M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.